NCT00638391

Brief Summary

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2005

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2005

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

March 13, 2008

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 19, 2008

Completed
Last Updated

March 20, 2008

Status Verified

March 1, 2008

First QC Date

March 13, 2008

Last Update Submit

March 19, 2008

Conditions

Breast Cancer

Keywords

Primary early MCaArimidex

Outcome Measures

Primary Outcomes (1)

  • evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions

    12 months

Secondary Outcomes (2)

  • description of population treated with anastrozole

    12 months

  • further information about the change of specific laboratory parameters

    12 months

Study Arms (1)

1

all patients treated with Anastrozole

Drug: Anastrozole

Interventions

AnastrozoleDRUG
Also known as: Arimidex
1

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample

You may qualify if:

  • Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Anastrozole

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

NitrilesOrganic ChemicalsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • H Brasch

    AstraZeneca Germany

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 13, 2008

First Posted

March 19, 2008

Study Start

May 1, 2005

Study Completion

March 1, 2007

Last Updated

March 20, 2008

Record last verified: 2008-03